NCT07736911 Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy.
| NCT ID | NCT07736911 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Fu Jen Catholic University Hospital |
| Condition | GLP-1 |
| Study Type | INTERVENTIONAL |
| Enrollment | 140 participants |
| Start Date | 2026-06-01 |
| Primary Completion | 2029-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 140 participants in total. It began in 2026-06-01 with a primary completion date of 2029-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the impact of a one-week discontinuation of long-acting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) prior to Esophagogastroduodenoscopy on gastric preparation quality and the need for repeat esophagogastroduodenoscopy (EGD), in order to determine whether a one-week drug interruption constitutes an appropriate pre-procedural recommendation.
Eligibility Criteria
Inclusion Criteria: * • Current use of GLP-1 receptor agonists (GLP-1 RAs) or tirzepatide (defined as discontinuation for no more than one week). * Continuous GLP-1 RA use for at least 4 weeks, or treatment at a near-maximal maintenance dose. * Scheduled to undergo esophagogastroduodenoscopy (EGD) for any indication. * Age between 18 and 70 years. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Provision of written informed consent. * Outpatient status. * If currently receiving medications that stimulate or inhibit gastrointestinal motility, these agents must be discontinued at least 3 days prior to EGD. Exclusion Criteria: * • Severe comorbid conditions precluding safe EGD (e.g., unstable angina, recent myocardial infarction, heart failure, chronic respiratory disease, or bleeding diathesis). * History of prior upper gastrointestinal resection (stomach, intestine, or esophagus). * Any other condition deemed inappropriate by the treating physician. * Body mass index (BMI) \> 40 kg/m². * Liver cirrhosis. * Parkinson's disease. * Dementia. * Use of tricyclic antidepressants or opioid medications for more than 3 months.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07736911 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying GLP-1. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07736911 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 140 participants.
Is NCT07736911 currently recruiting?
Yes, NCT07736911 is actively recruiting participants. Contact the research team at ioudanny520@hotmail.com for enrollment information.
Where is the NCT07736911 trial being conducted?
This trial is being conducted at New Taipei City, Taiwan.
Who is sponsoring the NCT07736911 clinical trial?
NCT07736911 is sponsored by Fu Jen Catholic University Hospital. The trial plans to enroll 140 participants.